Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma

NCT03213626 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped There were no objective responses by patient 7.

Conditions

Pancreatic Adenocarcinoma Metastatic

Interventions

DRUG: Cabozantinib 40 MG
DRUG: Erlotinib 100Mg Tab

Sponsor

Patrick Joseph Loehrer Sr.

Collaborators

[object Object]